MD Anderson Cancer Center and Exscientia plc formed a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
Organon launched the distribution of Ontruzant, a biosimilar of Herceptin, in Canada, providing an additional treatment option for Canadian adults diagnosed with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
FDA has approved Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.
FDA has approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing EGFR mutation or anaplastic lymphoma kinase genomic tumor aberrations.
FDA approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma. This is the first pediatric approval for Adcetris.
Portage Biotech Inc., a clinical-stage immuno-oncology company focused on overcoming cancer treatment resistance, entered into an agreement with Merck.
FDA issued a revised draft guidance for industry, “Expanded Access to Investigational Drugs for Treatment Use Questions and Answers.”
Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products.
Carrum Health and AccessHope LLC formed a collaboration to bring cancer expertise to people living with cancer.
FDA approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for adult patients with unresectable hepatocellular carcinoma.
